Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics names new CEO
Ms Graham joined TorreyPines in 2004 as vice president of development. Ms Graham was then promoted to vice president of corporate development in 2005, COO in 2006 and
Ms Graham joined TorreyPines in 2004 as vice president of development. Ms Graham was then promoted to vice president of corporate development in 2005, COO in 2006 and
The Phase Ia study was a randomized, placebo-controlled, double-blind, ascending-dose clinical trial in 60 healthy male and female volunteers examining doses of MBX-2982 in the 10-1000mg range. All
The Valeo family of ceramic spinal intervertebral spacers is intended to aid in surgical correction and stabilization of the thoracolumbar spine. These implants are designed to restore the
Under the terms of the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’s proprietary drug
The trial will compare the bioavailability and penetration of the topically applied Voltaren gel (1% diclofenac) and Phosphagenics’s diclofenac (at 1% and 2% diclofenac concentrations). The trial is
Pursuant to the terms of the agreement, BioLineRx will develop and commercialize BL-5040, a new anti-hormone for the treatment of inflammatory diseases. Rights to the compound were also
According to the company, the HER-2 fluorescent in situ hybridization (FISH) probe is designed to detect amplification of the Her-2 gene in human breast cancer tissue. HER-2, also
Under the agreement, Antyra will obtain exclusive rights to develop and commercialize certain IGF antagonists discovered during the research and license collaboration agreement entered into between the companies
Bristol-Myers Squibb notified the company that it has initiated a Phase II trial for a small molecule discovered using a target provided by Athersys, thereby triggering a milestone
In this study, 20 patients were identified with stable coronary artery disease that were treated with chronic clopidogrel (75mg) and aspirin therapy and have high platelet reactivity (HPR).